The illusion of certainty: Health benefits and risks

The Illusion of Certainty: Health Benefits and Risks

Volumn , Issue , 2007, Pages 1-241

  Rifkin, Erik ^a   Bouwer, Edward ^b  

^a Rifkin and Associates   (United States)

^b The Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889983305     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-48572-0     Document Type: Book

References (173)

1. Zehr SC (1999) Scientists' representations of uncertainty. In: Friedman SM, Dunwoody S, Rogers CL (eds) Communicating uncertainty-media coverage of new and controversial science. Lawrence Erlbaum Associates, Publishers, London, 277 pp.
2. Gawande A (2002) Complications-a surgeon's notes on an imperfect science. Picador Publishers, New York, 269 pp.
3. Carson R (1962) Silent Spring. Houghton Mifflin Co., New York, 300 pp.
4. Ruckelshaus WD (1983) Science, risk, and public policy. Science 221(4615): 1026-1028.
5. Lave LB (1987) Health and safety risk analyses: information for better decisions. Science 236(4799):291-295.
6. Gotzsche PC, Olsen O (2000) Is screening for breast cancer with mammo-graphy justifiable? The Lancet 355(9198):129-134.
7. Fisher B, Constantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidous A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natnl Cancer Inst 90(18):1371-1388.
8. Mansley EC, McKenna MT (2001) Importance of perspective in economic analyses of cancer screening decisions. The Lancet 358(9288):1169-1173.
9. Russell C (1986) The View from the national beat. In: Friedman SM, Dunwoody S, Rogers CL (eds) Scientists and journalists: reporting science as news. Published for the American Association for the Advancement of Science by the Free Press, Macmillan, New York City, 333 pp.
10. Hochhauser M, Goldfarb NM (2005) (Mis)Communicating COX-2 clinical trial results. (Accessed July 2006); http://www.firstclinical.com.
11. Elting LS, Martin CG, Cantor SB, Rosenthal EB (1999) Influence of data display formats on physician investigators' decisions to stop clinical trials: prospective trial with repeated measures. BMJ 318:1527-1531.
12. Ruckelshaus WD (1983) Science, risk, and public policy. Science 221(4615): 1026-1028.
13. Goldstein B (1985) Risk assessment and risk management of benzene by the Environmental Protection Agency. In: Hoel DG, Merrill RA, Revera FP (eds) Banbury Report 19: Risk quantification and regulatory policy. Cold Spring Harbor Laboratory, New York, pp. 293-304.
14. U.S. Environmental Protection Agency (US EPA) (1984) National emission standards for hazardous air pollutants; regulation of benzene; response to public comments. Federal Register 49(23):478-493.
15. Raffensperger C, Tickner J (eds) (1999) Protecting public health and the environment: implementing the precautionary principle Island Press, Washington, D.C., 385
16. Leape J (1980) Quantitative risk assessment in regulation of environmental carcinogens. Harv Environ Law Rev 4(86):86-116.
17. Latin H (1997) Science, regulation, and toxic risk assessment. In: Molak V (ed.) Fundamentals of risk analysis and risk management. CRC press, Boca Raton, FL, pp. 303-323.
18. U.S. EPA (1986) Risk assessment guidelines of 1986, EPA/600/8-82/045, August 1987.
19. Kurland L, Faro S, Siedler H (1960) Minamata disease. World Neurol 1:320-325.
20. NRC (National Research Council, U.S.) (2001) A risk-management strategy for PCB-contaminated sediments. National Academy Press, Washington, D.C., 452 pp.
21. NRC (National Research Council, U.S.) (1983) Risk assessment in the federal government: managing the process. National Academy Press, Washington, D.C., 191 pp.
22. Calabrese EJ (1987) Animal extrapolation: a look inside the toxicologist's black box. Environ Sci Tech 21(7):618-623.
23. Morgan MG, Henrion M (1990) Uncertainty: a guide to dealing with uncertainty in quantitative risk and policy analysis. Cambridge University Press, Cambridge, England, 332 pp.
24. Slovic P (2002) Trust, emotion, sex, politics, and science: surveying the riskassessment battlefield (Ch. 27). In: Paustenbach DJ (ed) Human and ecological risk assessment: theory and practice. Wiley-Interscience, New York City, pp. 1377-1397.
25. Wiener JB (2002) Precaution in a multirisk world (Ch. 32). In: Paustenbach DJ (ed) Human and ecological risk assessment: theory and practice. Wiley-Interscience, New York City, pp. 1509-1531.
26. Williams PRD, Paustenbach DJ (2002) Risk characterization (Ch. 5). In: Paustenbach DJ (ed) Human and ecological risk assessment: theory and practice. Wiley-Interscience, New York City, pp. 293-366.
27. Gold LS, Ames BN, Slone TH (2002) Misconceptions about the causes of cancer (Ch. 29). In: Paustenbach DJ (ed) Human and ecological risk assessment: theory and practice. Wiley-Interscience, New York City, pp. 1415-1460.
28. U.S. EPA (1985) Principles of risk assessment: a nontechnical review. Prepared by Environ Corporation for a risk assessment workshop, Easton, MD, March 17-18.
29. National Research Council (NRC) (1983) Risk assessment in the federal government: managing the process. National Academy Press, Washington, D.C., 191 pp.
30. Calabrese EJ (1987) Animal extrapolation: a look inside the toxicologist's black box. Environ Sci Tech 21(7): 618-623.
31. Paustenbach DJ (2002) Exposure assessment (Ch. 4), In: Paustenbach DJ (ed) Human and ecological risk assessment: theory and practice. Wiley-Interscience, New York City, pp. 189-291.
32. National Research Council (NRC) (1999) Environmental cleanup at navy facilities. National Academy Press, Washington, D.C., 143 pp.
33. Hattis D (2004) The conception of variability in risk analysis: developments since 1980, In: McDaniels T, Small MJ (eds) Risk analysis and society: an interdisciplinary characterization of the field. Cambridge University Press, Cambridge, United Kingdom, pp. 15-45.
34. National Research Council (1993) Issues in risk assessment. National Academies Press, Washington, D.C., 374 pp.
35. Sergeant A (2002) Ecological risk assessment: history and fundamentals (Ch. 6). In: Paustenbach DJ (ed) Human and ecological risk assessment: theory and practice. Wiley-Interscience, New York City, pp. 369-442.
36. Cullen AC, Small MJ (2004) Uncertain risk: the role and limits of quantitative assessment. In: McDaniels T, Small MJ (eds) Risk analysis and society: an interdisciplinary characterization of the field. Cambridge University Press, Cambridge, United Kingdom, pp. 163-212.
37. Ramaswami A, Milford JB, Small, MJ (2005) Integrated environmental modeling: pollutant transport, fate, and risk in the environment. John Wiley and Sons, Inc., Hoboken, NJ, 678 pp.
38. Wilson R, Crouch EAC (1987) Risk assessment and comparisons: an introduction. Science 236(4799):267-270.
39. Thompson KM, Bloom DL (2000) Communication of risk assessment information to risk managers. J Risk Research 3(4):333-352.
40. Hogue C (2006) Changes for research at EPA. Chemical and Engineering News 84(20):38-41.
41. Solomon DH, Avorn J (2005) Coxibs, science, and the public trust, an editorial. Arch Intern Med 165:158-160.
42. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective nonsteroidal anti-inflammatory drugs: nested case-control study. The Lancet 365(9458):475-481.
43. Dai C, Stafford RS, Alexander GC (2005) National trends in cyclooxygenase-2 inhibitor use since market release, Nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med 165(2):171-177.
44. Green GA (2001) Understanding NSAIDs: from aspirin to COX-2. Clin Cornerstone 3(5):50-59
45. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg, KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: a randomized controlled trial. JAMA 284(10):1247-1255.
46. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Bosi Ferraz M, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ for the VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343(21):1520-1528.
47. Hochhauser M, Goldfarb NM (2005) (Mis) Communicating COX-2 clinical trial results. (Accesed July 2006); http://www.firstclinical.com
48. Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb, RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK, PLCO Project Team (2005) Prostate cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screening round of a randomized trial. J Nat Can Instit 97(6):433-438.
49. Surveillance, Epidemiology, and End Results (SEER) Program (May 1997) Public use CD-ROM (1973-94) by the National Cancer Institute, DCPC, Surveillance Program, Cancer Statistics Branch.
50. U.S. Preventive Services Task Force (1996) Guide to Clinical Preventive Services, 2nd ed. Lippincott Williams & Wilkins, Baltimore, 953 pp.
51. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level
52. Lefevre ML, (1998) Prostate cancer screening: more harm than good? American Family Physician 58(2):432-438
53. Keetch DW, Catalona WJ, Smith DS (1994) Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151(6):1571-1574.
54. Ries LAG, Eisner MP, Kosary CL, Hanke BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK (eds) (2004) SEER cancer statistics review, 1975-201. National Cancer Institute, Bethesda, MD, (available online at http://seer. cancer.gov/csr/1975-2001).
55. Eichler K, Wilby J, Hempel S, Myers L, Kleijnen J (2005) Diagnostic value of systematic prostate biopsy methods in the investigation for prostate cancer: a systematic review (CRD Report 29). University of York, York, 215 pp.
56. Ravnskov U (2000) The cholesterol myths. New Trends Publishing, Inc., Washington, D.C., 305 pp.
57. American Heart Association (2006) Heart disease and stroke statistics-2006 update. Circulation 113(6):e85-151.
58. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). JAMA 285(19):2486-2497.
59. Ridker PM (2003) High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Amer J Card 92(4 supp 2):17K-22K.
60. DeBakey ME, Glaeser DH (2000) Patterns of atherosclerosis: effect of risk factors on recurrence and survival-analysis of 11,890 cases with more than 25-year follow-up. Amer J Card 85(9):1045-1053.
61. Kannel WB, Dawber TR, Friedman GD, Glennon WE, McNamara PM (1964) Risk factors in coronary heart disease: an evaluation of several serum lipids as predictors of coronary heart disease; The Framingham Study. Ann Intern Med 61:888-899.
62. Castelli WP, Anderson K (1986) A population at risk: Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Medicine 80(2 supp 1):23-32.
63. World Health Organization (WHO) (1982) Prevention of coronary heart disease, report of a WHO expert committee, Technical Report Series No. 678, WHO, Geneva, 53 pp.
64. Anonymous (1989) Importance of knowing HDL level emphasized. Internal Medicine News: the Leading Independent Newspaper for the Internist, November 1-14.
65. Kannel WB, Castelli WP, Gordon T (1979) Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham Study. Ann Intern Med 90(1):85-91.
66. Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, Kjelsberg MO (1986) Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT (Multiple Risk Factor Intervention Trial). Amer Heart J 112(4):825-836.
67. Stamler J, Wentworth D, Neaton JD (1986) Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256(2):2823-2828.
68. Hayward RA, Hofer TP, Vijan S (2006) Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med 145(7):520-530.
69. Fuhrmans V (2001) European panel to conduct review of cholesterol drugs. Wall Street Journal, New York, 10 August
70. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr., Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr., Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110(2):227-239.
71. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 366(9493):1267-1278.
72. Center for Science in the Public Interest (2004) Washington, (released 23 Sept. 2004, accessed Oct. 2006),.
73. Therapeutics Initiative (2003) Do statins have a role in primary prevention? University of British Columbia, Vancouver, (released 16 Oct. 2003, accessed Oct. 2006),.
74. Golomb BA, Criqui MH (2006) Statin Adverse Effects. University of California San Diego Statin Effects Study Group, (updated 2 Aug. 2006, accessed Oct. 2006),.
75. Talbert RL (2006) Safety issues with statin therapy. J Am Pharm Assoc 46(4):479-488.
76. Davidson M, Jacobson T (2001) How statins work: the development of cardiovascular disease and its treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Medscape Continuing Medical Education (CME) Professional Credit Activity.
77. Vaughan CJ, Murphy MB, Buckley BM (1996) Statins do more than just lower cholesterol. Lancet 348(9034):1079-1082.
78. Massy ZA, Keane WF, Kasiske BL (1996) Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet 347(8994):102-103.
79. Liao JK, Laufs U (2005) Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45:89-118.
80. Kolovou G (2001) The Treatment of coronary heart disease: an update: Part 3: statins beyond cholesterol lowering. Curr Med Res Opinion 17(1):34-37.
81. Van de Wiel A, Caillard, CA (2002) Statins and the stroke-cholesterol paradox. Neth J Med 60(1):4-9.
82. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Eng J Med 353(3):238-248.
83. Regier, L (2006) Personal communication, Saskatoon City Hospital, 701 Queen St., Saskatoon, Sk Canada S7K0M7.
84. See also NNTs for statins in various risk groups-major trial data (standardized for 5 years), Table 1 (available online at).
85. American Heart Association (2006) Heart disease and stroke statistics-2006 update. Circulation 113(6):e85-151.
86. Jorgensen OD, Kronborg O, Fenger C (2002) A randomized study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 50(1):29-32.
87. American Cancer Society (2002) Cancer Facts & Figures 202. ACS, Atlanta, GA, 44 pp. (available at http://www.cancer.org/docroot/STT/stt-0-2002. asp).
88. American Cancer Society (2004) Cancer Facts & Figures 204. ACS, Atlanta, GA, 58 pp. (available at http://www.cancer.org/docroot/STT/stt-0-2004. asp).
89. U.S. Preventive Services Task Force (1996) Guide to clinical preventive services, 2nd ed. Lippincott Williams & Wilkins, Baltimore, 953 pp.
90. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F (1993) The Minnesota colon cancer control study: reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 328(19):1365-1371.
91. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham, CM (1996) Randomized controlled trial of faecaloccult-blood screening for colorectal cancer. Lancet 348(9040):1472-1477.
92. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O (1996) Randomized study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348(9040):1467-1471.
93. National Center for Health Statistics (2005) Health, United States, 2005, with chartbook on trends in the health of Americans. U.S. Government Printing Office, Hyattsville, Maryland, 535 pp.
94. Perez-Pena, R (2003) Smoking ban relies on voluntary compliance. The New York Times, March 28.
95. Centers for Disease Control and Prevention (2002) Cigarette smoking among adults-United States, 202. MMWR 53(20):427-431.
96. U.S. Department of Health and Human Services (2004) The health consequences of smoking: a report of the Surgeon General. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA, chapters available online at.
97. Jacobs DR, Adachi H, Mulder I, Kromhout D, Menotti A, Nissinen A, Blackburn H (1999) Cigarette smoking and mortality risk: twenty-five-year followup of the Seven Countries Study. Arch Intern Med 159:733-740.
98. Doll R, Peto R, Boreham J, Sutherland I (2006) Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 328(7455):1519-1527.
99. U.S. Environmental Protection Agency (2003) Water on tap: what you need to know, EPA 816-K-03-07. Office of Water, Washington, D.C., 32 pp. (also available online at http://www.epa.gov/safewater/wot/index.html).
100. Madigan MT, Martinko JM (2006) Brock biology of microorganisms, 11th ed. Pearson Prentice Hall, Upper Saddle River, NJ, 1088 pp.
101. Maier RM, Pepper IL, Gerba CP (2000) Environmental microbiology. Academic Press, San Diego, CA, 585 pp.
102. Brody H, Rip MR, Vinten-Johansen P, Paneth N, Rachman S (2000) Mapmaking and myth-making in Broad Street: the London cholera epidemic, 154. Lancet 356:64-68.
103. McGhee TJ (1991) Water supply and sewerage, 6th ed. McGraw-Hill, Inc., New York, NY, 704 pp.
104. Centers for Disease Control (2004) Surveillance for waterborne disease outbreaks associated with drinking water-United States 2001-202. MMWR Surveillance Summaries 53(SS08):23-45.
105. Viessman W Jr., Hammer MJ (2005) Water supply and pollution control, 7th ed. Pearson Prentice Hall, Upper Saddle River, NJ, 876 pp.
106. World Health Organization and United Nations Children's Fund (2000) Global Water supply and sanitation assessment 2000 report. WHO/UNICEF, Geneva 80 pp. (document also available online at http://www.who.int/water- sanitation-health/monitoring/globalassess/en/).
107. Montgomery MA, Elimelech M (2007) Water and sanitation in developing countries: including health in the equation. Env Sci Tech 41(1):17-24.
108. U.S. Environmental Protection Agency (2002) List of drinking water contaminants and MCLs. (accessed September 2006 at http://www.epa.gov/safewater/ contaminants/index.html).
109. National Research Council (2004) Review of the Army's technical guides on assessing and managing chemical hazards to deployed personnel. National Academy Press, Washington, D.C., 195 pp.
110. National Research Council (NRC) (1999) Health effects of exposure to radon. Committee on the Health Risks of Exposure to Radon (BEIR VI), National Academy Press, Washington, D.C., 487 pp.
111. Samet JM (1997) Epidemiologic studies of ionizing radiation and cancer: past successes and future challenges. Environmental Health Perspectives 105(4):883-889.
112. Donohue K, Royal H (1996) Importance of radon as a threat to public health. Otolaryngol Head Neck Surg 114:271-276.
113. Mendez D, Warner KE, Courant PN (1998) Effects of radon mitigation vs. smoking cessation in reducing radon-related risk of lung cancer. Am J Public Health 88(5):811-812.
114. Pawel DJ, Puskin JS (2004) The U.S. Environmental Protection Agency's assessment of risks from indoor radon. Health Physics 87(1):68-74.
115. Tracy BL, Krewski D, Chen J, Zielinski JM, Brand KP, Meyerhof D (2006) Assessment and management of residential radon health risks: a report from the Health Canada radon workshop. J of Toxicology and Environmental Health, Part A 69:735-738.
116. Environmental Protection Agency (EPA) (2005) A Citizen's guide to radon: a guide to protecting yourself and your family from radon, www.epa.gov/radon/ pubs/citguide.html.
117. Krewski D, Rai SN, Zielinski JM, Hopke PK (1999) Characterization of uncertainty and variability in residential radon cancer risks. Annals New York Academy of Sciences 895:245-272.
118. Lackey RL (1997) Ecological risk analysis. In: Molak V (ed.) Fundamentals of risk analysis and risk management. CRC Press, Boca Raton, pp. 87-97.
119. U.S. Environmental Protection Agency (1992) Framework for ecological risk assessment: EPA/630/R-92/01. US EPA Risk Assessment Forum, Washington, D.C., 41 pp.
120. Environmental Defense Fund (1997) News Release: 25 years after DDT ban, Bald Eagles, Osprey numbers soar. (available online at http://www. environmentaldefense. org/pressrelease.cfm?contentID=2446).
121. Center for Environmental and Regulatory Information Systems (1993) Spotted knapweed: fact sheet. US Department of Agriculture Animal and Plant Health Inspection Service (APHIS), Plant Protection and Quarantine (PPQ), Cooperative Agricultural Pest Survey (CAPS), (available online at http://www.ceris. purdue.edu/napis/index.html).
122. Evans EW (1993) Biological control agents for Utah weeds: the Knapweed seedhead gall flies-Entomology fact sheet no. 1. Utah State University Extension Service, Logan, UT, 4 pp.
123. Pearson DE, Callaway RM (2006) Biological control agents elevate hanta virus by subsidizing deer mouse populations. Ecol Lett 9(4):443-450.
124. Moran PJ (1988) Crown-of-thorns Starfish questions and answers. Australian Institute of Marine Science (AIMS), Queensland, 198 pp. (also available at http://www.aims.gov.au/pages/reflib/cot-starfish/pages/cot-000. html).
125. National Research Council (2004) Nonnative oysters in the Chesapeake Bay. The National Academies Press, Washington D.C. 326 pp.
126. Kennedy VS, Breisch LL (1983) Sixteen decades of political management of the oyster fishery in Maryland's Chesapeake Bay. J Envir Man 16(2): 153-171.
127. NOAA Chesapeake Bay Office (2004) Native oysters. (available online at).
128. Rothschild BJ, Ault JS, Goulletquer P, Heral, M (1994) Decline of the Chesapeake Bay oyster population: a century of habitat destruction and overfishing. Mar Ecol Prog Ser 111(1-2):29-39.
129. Burreson EM, Stokes NA, Friedman CS (2000) Increased virulence in an introduced pathogen: Haplosporidium nelsoni (MSX) in the Eastern oyster Crassostrea virginica. J Aquat Anim Health 12(1):1-8.
130. Ford SE, Tripp MR (1996) Diseases and defense mechanisms. In: Kennedy VS, Newell RIE, Eble AF (eds) The Eastern oyster: Crassostrea virginica. Maryland Sea Grant College Program Publication UM-SG-TS-96-01, College Park, pp. 581-660.
131. Kennedy VS, Newell RIE, Eble AF (eds) (1996) The Eastern oyster: Crassostrea virginica. Maryland College Sea Grant Program Publication UM-SG-TS-96-01, College Park 772 pp.
132. Haskin HH, Andrews JD (1988) Uncertainties and speculations about the life cycle of the Eastern oyster pathogen Haplosporidium nelsoni (MSX). In: Fisher WS (ed) Disease processes in marine bivalve mollusks. American Fisheries Society Special Publication 18, Bethesda, Maryland, pp. 5-22.
133. Carlton JT (2001) Introduced species in U.S. coastal waters: environmental impacts and management priorities. Pew Oceans Commission, Arlington, Virginia, 36 pp.
134. Sindermann CJ (1990) Principal diseases of marine fish and shellfish, 2nd ed., Academic Press, San Diego, 516 pp.
135. Hayak FA (1991) Economic freedom. Basil Blackwell, Oxford, p. 287.
136. Latin H (1997) Science, regulation, and toxic risk assessment. In: Molak, V (ed) Fundamentals of risk analysis and risk management. Lewis Publishers, Boca Raton, 472 pp.
137. Maryland Department of the Environment (2004) Water quality analyses of chromium in the Inner Harbor/Northwest Branch and Bear Creek portions of Baltimore Harbor in Baltimore City and Baltimore County, Maryland: Report to EPA Region III, MDE, Baltimore, 16 pp.
138. McGee BK, Fisher DJ, Yonkos LT, Ziegler GP, Turley S (1999) Assessment of sediment contamination, acute toxicity, and population viability of the estuarine amphipod Leptocheirus plumulosus in Baltimore Harbor, Maryland. Environ Toxicol Chem 18(10):2151-2160.
139. U.S. Environmental Protection Agency (2004) The incidence and severity of sediment contamination in the surface waters of the United States, National Sediment Quality Survey, 2nd ed., EPA-823-R-04-07. Office of Science and Technology, Washington, D.C., 280 pp.
140. National Research Council (2003) Bioavailability of contaminants in soils and sediments: processes, tools, and applications. National Academies Press, Washington, D.C., 432 pp.
141. Evanko CR, Dzombak DA (1997) Remediation of metals-contaminated soils and groundwater, technology evaluation report TE-9701. Ground-Water Remediation Technologies Analysis Center (GWRTAC), Pittsburgh, PA, 53 pp.
142. Rifkin E, Gwinn P, Bouwer EJ (2004) Chromium and sediment toxicity. Environ Toxicol Chem 38(14):276A-271A.
143. Boothman WS, Berry WJ, Serbst JR, Edwards PA (2000) Predicting toxicity of chromium-spiked sediments by using acid-volatile sulfide and interstitial water measurements. US EPA, National Health and Environmental Effects Research Laboratory, Atlantic Ecology Division, Narragansett, RI. Presented at: 6th Annual NAC/SETAC Conference, Newport, Rhode Island, April 2000.
144. Berry WJ, Boothman WS, Serbst JR, Edwards PA (2002) Effects of chromium in sediment: 1. toxicity tests with saltwater field sediments. US EPA, National Health and Environmental Effects Research Laboratory, Atlantic Ecology Division, Narragansett, RI. Presented at: SETAC 23rrd Annual Meeting, Salt Lake City, Utah, 16-20 November 2002.
145. Wang W, Griscom SB, Fisher NS (1997) Bioavailability of Cr(III) and Cr(VI) to marine mussels from solute and particulate pathways. Environ Sci Technol 31(2):603-611.
146. Agency for Toxic Substances and Disease Registry (2000) Toxicological profile for chromium. US Department of Health and Human Services, ATSDR, Atlanta, Georgia, (available online at < http://www.atsdr.cdc.gov/>).
147. US Environmental Protection Agency (1985) Ambient water quality criteria for chromium-1984, EPA 440/5-84-29. Office of Water, Washington, D.C., 99 pp.
148. Brumbaugh WG, May TW, Wiedmeyer RH, Besser JM, Ingersoll CG (2002) Effects of chromium in sediment: 4. monitoring of chromium in sediment, pore water, and overlying water of Cr(VI) spiked freshwater sediments. U.S Geological Survey. Presented at: SETAC 23rd Annual Meeting Salt Lake City, Utah, 16-20 November 2002.
149. Gotzsche PC, Olsen O (2000) Is screening for breast cancer with mammo graphy justifiable? Lancet 355(9198):129-134.
150. Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW (2003) Mammog-raphy service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 361(9367):1405-1410.
151. The lifetime risk data mentioned throughout this chapter is available online from the National Cancer Institute (www.nci.gov) and the National Institutes of Health (www.nih.gov). 1.
152. Environmental Protection Agency (2005) A citizen's guide to radon: a guide to protecting yourself and your family from radon, EPA 402-K-02-06. EPA, Indoor Environments Division, Washington, D.C., 16 pp, (also available online at).
153. US Food and Drug Administration (1973) Compounds used in foodproducing animals, procedures for determining acceptability of assay methods used for assuring the absence of residues in edible products of such animals. Proposed rule, Federal Register, July 19:19226-19230.
154. Kelly KE (1991) The myth of 10 as a definition of acceptable risk. (Updated from a paper originally presented at the 84th annual meeting of the Air & Waste Management Association, Vancouver, B.C., Canada, June 16-21, 1991).
155. Howe HL, Wu X, Ries LA, Cokkinides V, Ahmed F, Jemal A, Miller B, Williams M, Ward E, Wingo PA, Ramirez A, Edwards BK (2006) Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 107(8):1711-1742.
156. Kiberstis PA, Travis J (2006) Celebrating a glass half-full. Science 312(5777):1157.
157. National Cancer Institute (2001) PLCO cancer screening trial completes recruitment. (Dated 26 July 2001, accessed Oct. 2006 at http://www.cancer. gov/newscenter/plcopr/).
158. American Cancer Society (accessed 10/18/2006) Overview: prostate cancer. (available at).
159. Jacobsen SL, Katusic SK, Bergstralh EJ, Oesterling JE, Ohrt D, Klee GG, Chute CG, Lieber MM (1995) Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 274(18):1445-1449.
160. Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olsen RM, Ross CA (1996) Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program, The Prostate Cancer Education Council. Urology 47(6):863-869.
161. Zoorob R, Anderson R, Cefalu C, Sidani M (2001) Cancer screening guidelines. Am Fam Physician 63(6):1101-1112.
162. Harris R, Lohr KN (2002) Screening for prostate cancer: an update of the evi-dence for the United States Preventative Services Task Force. Ann Intern Med 137(11):917-929.
163. Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK; PLCO Project Team (2005) Prostate cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screening round of a randomized trial. JCNI 97(6):433-438.
164. Bowker AH, Lieberman GJ (1972) Engineering statistics, 2nd ed. Prentice-Hall, Englewood Cliffs, NJ, 641 pp.
165. Olive JD, Clark VA (1974) Applied statistics: analysis of variance and regression. John Wiley & Sons, New York, NY, 387 pp.
166. Williams PRD, Paustenbach, DJ (2002) Chapter 5: Risk characterization. In: Paustenbach DJ (ed) Human and ecological risk assessment: theory and practice, pp. 293-366.
167. Morgan MG, Henrion M (1990) Uncertainty: a guide to dealing with uncertainty in quantitative risk and policy analysis. Cambridge University Press, Cambridge, England, 332 pp.
168. Cullen AC, Small MJ (2004) Uncertain risk: the role and limits of quantitative assessment. In: McDaniels T, Small MJ (eds) Risk analysis and society: an interdisciplinary characterization of the field. Cambridge University Press, Cambridge, United Kingdom, pp. 163-212.
169. Ramaswami A, Milford JB, Small, MJ (2005) Integrated environmental modeling: pollutant transport, fate, and risk in the environment. John Wiley and Sons, Inc., Hoboken, NJ, 678 pp.
170. Kannel WB, Castelli WP, Gordon T (1979) Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham Study. Ann Intern Med 90(1):85-91.
171. Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, Kjelsberg MO (1986) Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT (Multiple Risk Factor Intervention Trial). Amer Heart J 112(4):825-836.
172. Stamler J, Wentworth D, Neaton JD (1986) Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256(2):2823-2828.
173. Centers for Disease Control and Prevention (2003) Cholesterol status among adults in the United States, national health and nutrition examination survey. National Center for Health Statistics, Hyattsville, MD, (available online at http://www.cdc.gov/nchs/data/nhanes/databriefs/adultcholesterol.pdf).